Barclays Maintains Equal-Weight on Anteris Technologies Glb, Lowers Price Target to $9
Barclays analyst Matt Miksic maintains Anteris Technologies Glb (NASDAQ:AVR) with a Equal-Weight and lowers the price target from $10 to $9.
Last updated: 2026-11-13 18:00:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Anteris Technologies Global Corp. (AVR) operates in the ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES sector and is listed on NASDAQ. The stock is currently priced at $5.51, with a market capitalization of $571.11M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.30 to $11.06. This page covers its latest market performance, valuation, price trends and company information.
$571.11M | |
$5.81 | |
$5.98 | |
$5.38 | |
$5.86 | |
486.49K | |
1.12M | |
-- | |
$11.06 | |
$3.30 | |
-- | |
-- |
Anteris Technologies Global Corp. (AVR) is currently trading at $5.51 as of 2026-11-13 17:59:00, down 5.89% ($0.35) from the previous close of $5.86
During today's regular trading session, AVR has traded between $5.38 and $5.98, with a trading volume of 486.49K shares. The current price is near the lower end of today's range.
Over the past seven days, Anteris Technologies Global Corp. (AVR) moved from $5.58 to $5.51, representing a decline of 1.25% ($0.07).
The stock traded between $5.38 and $6.26 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 896.31 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 28.5%
AVR is currently trading at $5.51, placing it 28.5% of the way from its 52-week low of $3.30 to its 52-week high of $11.06. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
| Industry | ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES |
| Employees | 174 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Anteris Technologies Global Corp. and AVR stock.
Barclays analyst Matt Miksic maintains Anteris Technologies Glb (NASDAQ:AVR) with a Equal-Weight and lowers the price target from $10 to $9.
The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.
Eligible investors can buy real shares of Anteris Technologies Global Corp. (AVR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to AVR, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between AVR shares and USD.
AVR Shares to USD
1.00 AVR shares = 5.51 USD
Calculations are estimates based on the latest available price and are for reference only.